CN109689103A - 用于抑制5-ht2b激动剂的形成的制剂及其使用方法 - Google Patents

用于抑制5-ht2b激动剂的形成的制剂及其使用方法 Download PDF

Info

Publication number
CN109689103A
CN109689103A CN201780051892.XA CN201780051892A CN109689103A CN 109689103 A CN109689103 A CN 109689103A CN 201780051892 A CN201780051892 A CN 201780051892A CN 109689103 A CN109689103 A CN 109689103A
Authority
CN
China
Prior art keywords
fenfluramine
drug
inhibitor
days
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780051892.XA
Other languages
English (en)
Chinese (zh)
Inventor
斯蒂芬·J·法尔
布鲁克斯·博伊德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zogenix International Ltd
Original Assignee
Zogenix International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59955585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN109689103(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zogenix International Ltd filed Critical Zogenix International Ltd
Priority to CN202510282017.9A priority Critical patent/CN120241681A/zh
Publication of CN109689103A publication Critical patent/CN109689103A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/105—Persulfides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201780051892.XA 2016-08-24 2017-08-02 用于抑制5-ht2b激动剂的形成的制剂及其使用方法 Pending CN109689103A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510282017.9A CN120241681A (zh) 2016-08-24 2017-08-02 用于抑制5-ht2b激动剂的形成的制剂及其使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662379183P 2016-08-24 2016-08-24
US62/379,183 2016-08-24
US201762515383P 2017-06-05 2017-06-05
US62/515,383 2017-06-05
PCT/IB2017/054740 WO2018037306A1 (en) 2016-08-24 2017-08-02 Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510282017.9A Division CN120241681A (zh) 2016-08-24 2017-08-02 用于抑制5-ht2b激动剂的形成的制剂及其使用方法

Publications (1)

Publication Number Publication Date
CN109689103A true CN109689103A (zh) 2019-04-26

Family

ID=59955585

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510282017.9A Pending CN120241681A (zh) 2016-08-24 2017-08-02 用于抑制5-ht2b激动剂的形成的制剂及其使用方法
CN201780051892.XA Pending CN109689103A (zh) 2016-08-24 2017-08-02 用于抑制5-ht2b激动剂的形成的制剂及其使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202510282017.9A Pending CN120241681A (zh) 2016-08-24 2017-08-02 用于抑制5-ht2b激动剂的形成的制剂及其使用方法

Country Status (15)

Country Link
US (6) US20180055789A1 (enExample)
EP (2) EP3518975B1 (enExample)
JP (3) JP2019526544A (enExample)
KR (3) KR20190040237A (enExample)
CN (2) CN120241681A (enExample)
AU (3) AU2017315273B2 (enExample)
CA (1) CA3032996C (enExample)
ES (1) ES3029536T3 (enExample)
IL (2) IL290727B2 (enExample)
MX (2) MX2019001799A (enExample)
RU (2) RU2746000C2 (enExample)
SG (1) SG11201900975XA (enExample)
TW (3) TWI722233B (enExample)
WO (1) WO2018037306A1 (enExample)
ZA (1) ZA201900766B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118873517A (zh) * 2024-07-05 2024-11-01 上海柯西医药科技发展有限公司 大麻二酚与5-ht2b受体激动剂的组合的用途

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
HRP20250898T1 (hr) 2015-12-22 2025-09-26 Zogenix International Limited Pripravci fenfluramina i postupci njihove pripreme
JP2019526544A (ja) * 2016-08-24 2019-09-19 ゾゲニクス インターナショナル リミテッド ５−ｈｔ２ｂアゴニストの形成を阻害するための製剤およびその使用方法
US20190091179A1 (en) 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
GB201715919D0 (en) 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
WO2019216919A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
US10517841B1 (en) 2018-06-14 2019-12-31 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
CN111867822B (zh) 2018-06-15 2022-06-10 株式会社Lg化学 装饰构件
SG11202104378SA (en) 2018-11-19 2021-05-28 Zogenix International Ltd Methods of treating rett syndrome using fenfluramine
WO2020112460A1 (en) * 2018-11-30 2020-06-04 Zogenix International Limited A method of treating refractory epilepsy syndromes using fenfluramine enantiomers
EP4031114A1 (en) 2019-09-17 2022-07-27 Zogenix International Limited Methods of treating epileptic patients with fenfluramine
IL293136A (en) * 2019-11-21 2022-07-01 Shinkei Therapeutics Inc Combined medical treatment with cannabidiol and/or cubicitate
WO2021222009A1 (en) * 2020-04-30 2021-11-04 Taho Pharmaceuticals Ltd. Clobazam transdermal delivery system and uses thereof
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
WO2023101866A1 (en) * 2021-12-01 2023-06-08 Zogenix International Limited Fenfluramine for treatment of conditions associated with spreading depolarization
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same
WO2025174742A1 (en) * 2024-02-12 2025-08-21 Corcept Therapeutics Incorporated Concomitant administration of miricorilant with cyp2c19 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140329908A1 (en) * 2013-05-03 2014-11-06 Berten Ceulemens Method For The Treatment of Dravet Syndrome

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL270984A (enExample) 1960-11-05
US3117160A (en) 1961-07-27 1964-01-07 Pfizer & Co C Aralkylamines
US3198834A (en) 1964-07-27 1965-08-03 Snc Science Union Et Compagnie Optical isomers of trifluoromethylated phenethylamines
GB1254332A (en) 1969-02-27 1971-11-17 Science Union & Cie Amino acids and their derivatives and processes for preparing them
DE2143204C3 (de) 1971-08-28 1979-09-27 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt N-Fluoralkyl-phenylisopropylamin-Derivate und deren Salze, Verfahren zu deren Herstellung und Arzneimittel auf deren Basis
DE2150399A1 (de) 1971-10-09 1973-04-12 Hoechst Ag Neue oxime
GB1413078A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof
GB1413070A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of - norfenfluramine and - fenfluramine and salts thereof
US4452815A (en) 1980-06-16 1984-06-05 Massachusetts Institute Of Technology Method of utilizing d,l-fenfluramine for modifying feeding behavior
US4309445A (en) 1980-06-16 1982-01-05 Massachusetts Institute Of Technology d-Fenfluramine for modifying feeding behavior
DE3717434C1 (de) 1987-05-23 1988-09-15 Degussa Verfahren zur Herstellung von m-Trifluormethylphenylacetonitril
US4857553A (en) 1987-08-06 1989-08-15 A. H. Robins Company, Incorporated Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents
KR890003368A (ko) 1987-08-06 1989-04-14 원본미기재 특정의 치환된 페닐알킬아미노(및 아미노산) 유도체 및 기타 세로토닌농도 저하제로 오심 및 구토를 치료하는 방법
HU204497B (en) 1989-10-09 1992-01-28 Chinoin Gyogyszer Es Vegyeszet Process for producing phenfluramine
IT1238686B (it) 1990-02-09 1993-09-01 Lab Mag Spa Procedimento per la preparazione di levo e destro fenfluramina
FR2663539B1 (fr) * 1990-06-22 1994-10-07 Adir Utilisation de la d-fenfluramine pour l'obtention de medicaments destines au traitement des deficiences immunitaires chez le sujet age.
FR2684552B1 (fr) 1991-12-06 1995-04-28 Adir Utilisation de la d-fenfluramine et de derives de la fenfluramine dans le traitement de l'hypertension chez des sujets insulino-resistants.
FR2685204B1 (fr) * 1991-12-19 1995-06-16 Palmer Research Compositions pharmaceutiques pour l'administration transcutanee de la fenfluramine.
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
ES2139750T3 (es) 1993-08-06 2000-02-16 Upjohn Co 2-aminoindanos como ligandos selectivos d3 de la dopamina.
US5834477A (en) 1993-12-08 1998-11-10 The United States Of America As Represented By The Secretary Of The Army Opiate analgesic formulation with improved safety
US5412102A (en) 1994-05-27 1995-05-02 Syntex (U.S.A.) Inc. Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
PT762877E (pt) 1994-06-03 2001-08-30 Thejmde Trust Arilalquilaminas meta-substituidas e suas aplicacoes terapeuticas e de diagnostico
IT1298349B1 (it) 1996-05-29 2000-01-05 Alfa Chem Ital Processo per la produzione di 1 - (3-trifluorometil) fenil-propan- 2-one intermedio nella sintesi della fenfluramina
IT1292885B1 (it) 1997-04-28 1999-02-11 Alfa Chem Ital Processo per la produzione degli isomeri (r) ed (s)- alfa -metil-3- (trifluorometil)benzene-etanamina.
EP0920864A1 (en) 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
US20020098175A1 (en) 1998-06-16 2002-07-25 Zohoungbogbo Mathias C. Dietetic food composition and dietetic method using such composition
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
EP1140061B1 (en) 1998-12-23 2003-05-02 Orphan Medical Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
US20080103179A1 (en) 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7124031B1 (en) 2000-05-11 2006-10-17 Medco Health Solutions, Inc. System for monitoring regulation of pharmaceuticals from data structure of medical and labortory records
US20020038310A1 (en) 2000-07-17 2002-03-28 Reitberg Donald P. Single-patient drug trials used with accumulated database: genomic markers
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
EP1392262A1 (en) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
WO2003000047A2 (en) 2001-06-22 2003-01-03 Universite Catholique De Louvaine Hydrogel beads or capsules as artificial media for insects oviposition and rearing of endoparasitoids
BR0211794A (pt) 2001-07-31 2004-11-03 Wyeth Corp Composição farmacêutica e método para mascarar o sabor de pelo menos um composto farmaceuticamente ativo de sabor desagradável
AUPR732601A0 (en) 2001-08-28 2001-09-20 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of amines such as ephedrine and inter mediates
RU2317104C2 (ru) 2001-09-24 2008-02-20 Импиэриэл Инноувейшнс Лимитид Способ модификации пищевого поведения и применение pyy или его агониста в качестве средства для модификации пищевого поведения
PL205971B1 (pl) 2001-09-24 2010-06-30 Imp Innovations Ltd Zastosowanie PYY₃-₃₆ do wytwarzania leku na ograniczanie apetytu, zmniejszenie otyłości lub do zapobiegania otyłości
US6599901B1 (en) 2001-11-19 2003-07-29 Hoffman-La Roche Inc. Pyridone substituted benzothiazole derivatives
US7101572B2 (en) 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
WO2003077847A2 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
CA2479744A1 (en) 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
US7668730B2 (en) 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
WO2005004865A1 (en) 2003-07-08 2005-01-20 Georg-August-Universität Göttingen Use of 5-ht4(a)-serotonin receptor agonists
GB0410266D0 (en) 2004-05-07 2004-06-09 Ketocytonyx Inc Treatment of apoptosis
US20050260610A1 (en) 2004-05-20 2005-11-24 Kurtz Richard E Method for diagnosing and prescribing a regimen of therapy for human health risk
US9820658B2 (en) 2006-06-30 2017-11-21 Bao Q. Tran Systems and methods for providing interoperability among healthcare devices
KR20070046185A (ko) 2004-09-23 2007-05-02 메르츠 파마 게엠베하 운트 코. 카가아 소아 행동장애의 치료를 위한 메만틴
AU2006225980A1 (en) 2005-03-21 2006-09-28 Health-Smart Limited System for continuous blood pressure monitoring
AU2006251213A1 (en) 2005-05-25 2006-11-30 Janssen Pharmaceutica N.V. Pediatric formulation of topiramate
EP1904630A4 (en) 2005-06-16 2009-10-21 Bionomics Ltd METHODS OF TREATING AND DIAGNOSING EPILEPSY BY DETECTING MUTATIONS OF THE SCN1A GENE
GB0515090D0 (en) 2005-07-22 2005-08-31 Birmingham Res & Dev Ltd Novel epilepsy treatment
WO2007031846A2 (en) 2005-09-14 2007-03-22 University Of The Witwatersrand, Johannesburg Pharmaceutical composition
CA2622967A1 (en) 2005-09-19 2007-03-29 Biolert Ltd. A system and method for detecting an epileptic event
DK2508621T3 (en) 2005-11-29 2015-01-12 Childrens Hosp Medical Center Optimization and individualization of drug selection and dosage
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2007079181A2 (en) 2005-12-28 2007-07-12 Neurovista Corporation Methods and systems for recommending an action to a patient for managing epilepsy and other neurological disorders
CA2637792A1 (en) 2006-02-06 2007-08-16 Novartis Ag Combination of organic compounds
DE102006030113B4 (de) 2006-06-28 2009-02-12 Chemische Fabrik Budenheim Kg Graphitfreier Hochtemperatur-Schmierstoff
JP2010501597A (ja) 2006-08-31 2010-01-21 ザ ガバナーズ オブ ザ ユニバーシティー オブ アルバータ 正のアロステリックａｍｐａ受容体モジュレーターを用いて呼吸抑制を阻害する方法
CA2662574A1 (en) * 2006-09-22 2008-03-27 Novartis Ag Heterocyclic organic compounds
US20080243584A1 (en) 2007-01-31 2008-10-02 Quintiles Transnational Corp. Methods and systems for allocating representatives to sites in clinical trials
WO2008096271A2 (en) 2007-02-08 2008-08-14 Ralf Gold Neuroprotection in demyelinating diseases
WO2008104524A1 (en) 2007-02-28 2008-09-04 Smithkline Beecham Corporation Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase
US20100297181A1 (en) * 2007-12-26 2010-11-25 Eisai R&D Management Co., Ltd. AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
CA2905541C (en) 2008-01-09 2020-02-11 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
EP2331088A4 (en) 2008-08-06 2011-10-12 Gosforth Ct Holdings Pty Ltd COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
WO2010020585A1 (en) 2008-08-18 2010-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin reuptake inhibitors for the treatment of rett syndrome
RU2674150C1 (ru) 2008-09-05 2018-12-05 Грюненталь Гмбх Фармацевтическая комбинация
US8386274B1 (en) 2008-09-17 2013-02-26 Mckesson Financial Holdings Limited Systems and methods for a prescription safety network utilizing eligibility verification transactions
GEP20135723B (en) 2008-10-09 2013-01-10 Acraf Liquid pharmaceutical composition containing paracetamol
WO2010042780A2 (en) 2008-10-10 2010-04-15 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of Walter Reed Army Institute Of Research Methods and compositions for treating status epilepticus and seizures causing status epilepticus
TWI503101B (zh) 2008-12-15 2015-10-11 Proteus Digital Health Inc 與身體有關的接收器及其方法
EP2406765A4 (en) 2009-03-09 2014-12-31 Celgene Corp DEVICE FOR ADMINISTERING A MEDICAMENT TO A PATIENT WITH RESTRICTED PATIENT-SIDED ACCESS TO THE MEDICAMENT IN THE CASE OF CONTRAINDICATIONS AND APPLICATION METHOD THEREFOR
EP2419400A1 (en) 2009-04-15 2012-02-22 Research Triangle Institute Monoamine reuptake inhibitors
WO2010124137A1 (en) 2009-04-22 2010-10-28 Millennium Pharmacy Systems, Inc. Pharmacy management and administration with bedside real-time medical event data collection
US9453027B2 (en) 2009-07-27 2016-09-27 Daljit Singh Dhanoa Deuterium-enriched pyridinonecarboxamides and derivatives
US20110212171A1 (en) 2010-01-08 2011-09-01 Eurand, Inc. Taste masked topiramate composition and an orally disintegrating tablet comprising the same
EP2545522B1 (en) 2010-03-09 2017-07-26 Perceptimed, Inc. Medication verification and dispensing
WO2011119227A2 (en) 2010-03-25 2011-09-29 Columbia Northwest Pharmaceuticals, Llc Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients
JP2011221623A (ja) 2010-04-06 2011-11-04 Kakimori Suri 在宅診療支援システム及び方法
EP2571858B1 (en) 2010-05-21 2018-06-20 Research Triangle Institute Phenylmorpholines and analogues thereof
EP2399513B1 (en) 2010-06-23 2017-01-04 Qatar University Qstp-B System for non-invasive automated monitoring, detection, analysis, characterisation, prediction or prevention of seizures and movement disorder symptoms
US20140162942A1 (en) * 2010-07-30 2014-06-12 Anima Ghosal Inhibition of cyp3a drug metabolism
SG188362A1 (en) 2010-09-01 2013-04-30 Arena Pharm Inc Modified-release dosage forms of 5-ht2c agonists useful for weight management
US20120270848A1 (en) 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
JP2013540807A (ja) 2010-10-26 2013-11-07 アルファーマ ファーマシューティカルズ エルエルシー オピオイド過量投与によって誘発される呼吸抑制を減弱する製剤および方法
RU103209U1 (ru) 2010-10-29 2011-03-27 Общество С Ограниченной Ответственностью "Правовое Сопровождение Бизнеса" Клиническая информационная система
GB2487712B (en) * 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
US10183008B2 (en) * 2011-02-09 2019-01-22 University Of South Carolina Treatment of prolonged status epilepticus
JP5693325B2 (ja) 2011-03-29 2015-04-01 小林クリエイト株式会社 健診結果出力システム及び健診結果出力プログラム
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
US10092750B2 (en) 2011-11-11 2018-10-09 Neuroenabling Technologies, Inc. Transcutaneous neuromodulation system and methods of using same
US20140348966A1 (en) 2011-12-22 2014-11-27 Onesmo B. Balemba Garcinia buchananii baker compounds, compositions and related methods
CA2862816A1 (en) 2012-01-27 2013-08-01 Catalyst Pharmaceutical Partners Method of treating tourette's disorder with gaba-aminotransferase inactivators
US9346798B2 (en) 2012-02-13 2016-05-24 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
US20130218586A1 (en) 2012-02-21 2013-08-22 Frederic J. Huser Methods and elements for identifying the appropriate patient populations who can safely use prescription chronic care drugs that are switched to an over-the-counter regulatory status
JP6075973B2 (ja) 2012-06-04 2017-02-08 富士通株式会社 健康状態判定装置およびその作動方法
DE102012213040B4 (de) * 2012-07-25 2014-03-20 Infineon Technologies Ag Decoder für physikalisch nicht klonbare Funktionen mittels Schwellendekodierung und entsprechendes Verfahren
CA2891342A1 (en) 2012-11-15 2014-05-22 Galleon Pharmaceuticals, Inc. Novel orally bioavailable breathing control modulating compounds, and methods of using same
WO2014106825A2 (en) 2013-01-06 2014-07-10 Jonathan Rabinowitz Methods and devices for identifying improper medical reporting
HRP20201002T1 (hr) 2013-07-25 2020-10-16 Neuren Pharmaceuticals Limited Neuroprotektivni biciklički spojevi i metode za njihovo korištenje u tretmanu poremećaja autističnog spektra i neurorazvojnih poremećaja
RS61038B1 (sr) 2013-08-19 2020-12-31 Univ California Jedinjenja i metodi za lečenje epileptičnog poremećaja
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2015077057A1 (en) 2013-11-20 2015-05-28 Texas Southern University Methionine aminopeptidase inhibitors for treating infectious diseases
JP6147676B2 (ja) * 2014-01-07 2017-06-14 東芝テック株式会社 情報処理装置、店舗システム及びプログラム
CN103886415A (zh) 2014-03-25 2014-06-25 北京蝶禾谊安信息技术有限公司 药品管理方法和装置
CN106461677B (zh) 2014-04-22 2018-09-11 国立大学法人东北大学 肺高血压病的检查方法
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
WO2016003966A1 (en) 2014-06-30 2016-01-07 University Of Cincinnati Non-invasive detection of spreading depolarization using scalp electroencephalography
NZ730560A (en) 2014-09-29 2020-05-29 Zogenix International Ltd Control system for control of distribution of medication
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
EP4059522A1 (en) 2015-02-06 2022-09-21 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
EA201992474A3 (ru) 2015-02-25 2020-05-31 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа Агонисты 5ht для лечения нарушений
US10292996B2 (en) 2015-03-26 2019-05-21 The Trustees Of Columbia University In The City Of New York Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome
CN104800168A (zh) * 2015-04-08 2015-07-29 石家庄四药有限公司 司替戊醇干混悬剂及其制备方法
JP6668045B2 (ja) 2015-05-15 2020-03-18 ゾゲニクス インターナショナル リミテッド ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト
KR20250048602A (ko) 2015-06-17 2025-04-09 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 미토콘드리아 dna 고갈 증후군을 포함하는 불균형 뉴클레오타이드 풀에 의해 야기된 질환에 대한 데옥시뉴클레오타이드 요법
WO2017003822A1 (en) 2015-06-30 2017-01-05 Galleon Pharmaceuticals, Inc. Novel breathing control modulating compounds, and methods of making and using same
WO2017015309A1 (en) 2015-07-22 2017-01-26 John Hsu Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof
KR20180054584A (ko) 2015-08-24 2018-05-24 조게닉스 인터내셔널 리미티드 펜플루라민을 사용하여 레녹스-가스토 증후군을 치료하는 방법
US20220193082A1 (en) 2015-09-14 2022-06-23 Zogenix International Limited Combination treatment of specific forms of epilepsy
US20170071949A1 (en) 2015-09-14 2017-03-16 Zogenix International Limited Combination treatment of specific forms of epilepsy
EP3170807B1 (en) 2015-11-23 2019-12-11 Frau Pharma S.r.l. New method for synthesis of fenfluramine
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
HRP20250898T1 (hr) 2015-12-22 2025-09-26 Zogenix International Limited Pripravci fenfluramina i postupci njihove pripreme
WO2017122701A1 (ja) 2016-01-14 2017-07-20 旭硝子株式会社 フッ素樹脂含有溶液、フッ素樹脂含有溶液の製造方法、塗料組成物および塗装物品
CN118340787A (zh) 2016-03-28 2024-07-16 武田药品工业株式会社 药物
US20190083425A1 (en) 2016-08-24 2019-03-21 Zogenix International Limited Formulation for inhibiting formation of 5-ht2b agonists and methods of using same
JP2019526544A (ja) 2016-08-24 2019-09-19 ゾゲニクス インターナショナル リミテッド ５−ｈｔ２ｂアゴニストの形成を阻害するための製剤およびその使用方法
US20180092864A1 (en) 2016-09-30 2018-04-05 Zogenix International Limited Compositions and methods for treating seizure disorders
JP7607302B2 (ja) 2017-02-08 2024-12-27 オービッド・セラピューティクス・インコーポレイテッド 発作性障害およびプラダー・ウィリー症候群の治療方法
CA3062247A1 (en) 2017-05-09 2018-11-15 Zogenix International Limited Methods of treating doose syndrome using fenfluramine
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
US20190247333A1 (en) 2017-09-26 2019-08-15 Zogenix International Limited Method of reduction in convulsive seizure frequency
WO2019067413A1 (en) 2017-09-26 2019-04-04 Zogenix International Limited USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS
US20190091176A1 (en) 2017-09-26 2019-03-28 Zogenix International Limited Method of treating selected patient population experiencing dravet syndrome
US20190091179A1 (en) 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
US11352882B2 (en) 2018-03-12 2022-06-07 Cameron International Corporation Plug assembly for a mineral extraction system
US12419970B2 (en) 2018-04-18 2025-09-23 The Trustees Of Columbia University In The City Of New York Gene therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes
WO2019216919A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
US10517841B1 (en) 2018-06-14 2019-12-31 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
JP2021530481A (ja) 2018-07-10 2021-11-11 ゾゲニクス インターナショナル リミテッド 肺高血圧症を有さない患者においててんかんまたはてんかん性脳症を処置するために使用するためのフェンフルラミン
KR20210061332A (ko) 2018-07-27 2021-05-27 제논 파마슈티칼스 인크. 뇌전증 치료 방법
SG11202104378SA (en) 2018-11-19 2021-05-28 Zogenix International Ltd Methods of treating rett syndrome using fenfluramine
WO2020112460A1 (en) 2018-11-30 2020-06-04 Zogenix International Limited A method of treating refractory epilepsy syndromes using fenfluramine enantiomers
WO2020176276A1 (en) 2019-02-25 2020-09-03 Zogenix International Limited A formulation for improving seizure control
US20210299064A1 (en) 2020-02-05 2021-09-30 Zogenix International Limited Method of treating patients with lennox-gastaut syndrome
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US20220096514A1 (en) 2020-09-29 2022-03-31 Zogenix International Limited Methods of treating thymidine kinase 2 deficiency by administering deoxycytidine and deoxythymidine
JP2024533015A (ja) 2021-09-01 2024-09-12 ゾゲニクス インターナショナル リミテッド 脱髄性の疾患および病状の処置のためのフェンフルラミン

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140329908A1 (en) * 2013-05-03 2014-11-06 Berten Ceulemens Method For The Treatment of Dravet Syndrome

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BASANAGOUD MUDIGOUDAR等: "Emerging Antiepileptic Drugs for Severe Pediatric Epilepsies", 《SEMINARS IN PEDIATRIC NEUROLOGY》 *
HABIBI M等: "The Impact of Psychoactive Drugs on Seizures and Antiepileptic Drugs", 《CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS》 *
VS HARITOS等: "Metabolism of dexfenfluramine in human liver microsomes and by recombinant enzymes: role of CYP2D6 and 1A2", 《PHARMACOGENETICS》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118873517A (zh) * 2024-07-05 2024-11-01 上海柯西医药科技发展有限公司 大麻二酚与5-ht2b受体激动剂的组合的用途

Also Published As

Publication number Publication date
AU2017315273A1 (en) 2019-03-07
US20200246281A1 (en) 2020-08-06
TWI776407B (zh) 2022-09-01
US20220125743A1 (en) 2022-04-28
RU2021106383A (ru) 2021-04-05
CA3032996A1 (en) 2018-03-01
WO2018037306A1 (en) 2018-03-01
KR20250040753A (ko) 2025-03-24
NZ750691A (en) 2021-06-25
US11406606B2 (en) 2022-08-09
AU2017315273B2 (en) 2021-04-29
CN120241681A (zh) 2025-07-04
JP2022180461A (ja) 2022-12-06
AU2021204250B2 (en) 2022-09-01
EP4201427A1 (en) 2023-06-28
EP3518975A1 (en) 2019-08-07
ES3029536T3 (en) 2025-06-24
TW202131908A (zh) 2021-09-01
US11759440B2 (en) 2023-09-19
TW202308601A (zh) 2023-03-01
SG11201900975XA (en) 2019-03-28
ZA201900766B (en) 2020-10-28
AU2022279469B2 (en) 2024-05-02
CA3032996C (en) 2025-05-06
EP3518975B1 (en) 2025-04-09
RU2019105059A (ru) 2020-09-25
IL264637B (en) 2022-04-01
KR20230021172A (ko) 2023-02-13
RU2019105059A3 (enExample) 2020-11-25
MX2023005140A (es) 2023-05-26
AU2022279469A1 (en) 2023-02-02
US20180055789A1 (en) 2018-03-01
IL290727B2 (en) 2023-12-01
JP2019526544A (ja) 2019-09-19
US20210267916A1 (en) 2021-09-02
TW201821071A (zh) 2018-06-16
IL290727A (en) 2022-04-01
US20190083424A1 (en) 2019-03-21
TW202432093A (zh) 2024-08-16
IL290727B1 (en) 2023-08-01
US11786487B2 (en) 2023-10-17
AU2021204250A1 (en) 2021-07-22
TWI722233B (zh) 2021-03-21
KR20190040237A (ko) 2019-04-17
US10603290B2 (en) 2020-03-31
RU2746000C2 (ru) 2021-04-05
US20210393550A1 (en) 2021-12-23
US11040018B2 (en) 2021-06-22
MX2019001799A (es) 2019-06-13
JP2024180450A (ja) 2024-12-26

Similar Documents

Publication Publication Date Title
CN109689103A (zh) 用于抑制5-ht2b激动剂的形成的制剂及其使用方法
JP2025036702A (ja) 神経認知障害、慢性疼痛を治療し、炎症を低減させる方法
Lacy et al. Chronic constipation: new diagnostic and treatment approaches
Staskin et al. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial
CA3161244A1 (en) Treatment of amyotrophic lateral sclerosis
Gómez‐Criado et al. Ziprasidone overdose: cases recorded in the database of Pfizer‐Spain and literature review
Künig et al. Unrecognised long-lasting tramadol-induced delirium in two elderly patients
Dickinson et al. Clinical guidelines for ibogaine-assisted detoxification
Beaini et al. Sirolimus potentiated angioedema: A case report and review of the literature
US20250375417A1 (en) Orexin receptor 2 (ox2r) agonist for use in narcolepsy type 1 (nt1)
JP2025531459A (ja) 神経変性疾患の治療におけるホウ酸塩誘導体の使用
Lingam A Comparative Study of Remission Occurrence in the Mono and add on Therapies during the Treatment of Epileptic Seizures and the Evaluation of Patients Knowledge on First Aid in Tertiary Care Hospital
WO2024054412A1 (en) Methods and compositions for treating amyotrophic lateral sclerosis
TW201244717A (en) Treatment of attention deficit/hyperactivity disease
HK40081935A (en) Treatment of amyotrophic lateral sclerosis
Hartley Science and health care-whence and whither
HK40007948A (en) Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
NZ750691B2 (en) Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
HK40012506B (en) Formulation comprising fenfluramine and cannabidiol and its use in the treatment of seizures
HK40012506A (en) Formulation comprising fenfluramine and cannabidiol and its use in the treatment of seizures

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40007948

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190426